Back to Interventions
Substance / Medication

Methyl aminolevulinate

SNOMED 409397005UMLS C1134467

Overview

Active Ingredient
methyl 5-aminolevulinate
RxNorm CUI
337068

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Solar keratosis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

40 trials linked to this intervention

40
Total Trials
6
Recruiting
13
With Results

Recent Trials

Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses

NCT00110682Phase 4Completed60 enrolled

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

NCT00115154Phase 4Completed270 enrolled

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

NCT00116649Phase 4Completed551 enrolled

Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head

NCT00204542Phase 4Completed418 enrolled

An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses

NCT00377273Phase 4Completed250 enrolled
View all 40 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
"A 10-years follow-up of Photodynamic Therapy for nodular basal cell carcinoma: a randomized comparing the effectiveness of Aminolevulinic acid-PDT, Methyl aminolevulinate-PDT, and surgery".
Salvio Ana Gabriela, Requena Michelle Barreto, Stringasci Mirian Denise et al. · Photodiagnosis Photodyn Ther · 2025
PMID: 40614840RCT
Long-term outcome of photodynamic therapy with hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion and methyl aminolevulinate for low-risk Basal Cell Carcinomas.
Salmivuori M, Grönroos M, Tani T et al. · Photodiagnosis Photodyn Ther · 2025
PMID: 39645015RCT
The impact of occlusive vs non-occlusive application of methyl aminolevulinate on the efficacy and tolerability of daylight photodynamic therapy for actinic keratosis.
Trave Ilaria, Salvi Ilaria, Serazzi Franco Aguirre et al. · Photodiagnosis Photodyn Ther · 2024
PMID: 38490345RCT
Long-Term Efficacy of Photodynamic Therapy with Fractionated 5-Aminolevulinic Acid 20% versus Conventional Two-Stage Topical Methyl Aminolevulinate for Superficial Basal-Cell Carcinoma.
van Delft Lieke C J, Nelemans Patty J, Kessels Janneke P H M et al. · Dermatology · 2022
PMID: 35598594RCTFull text (PMC)
Comparison of clinical and histologic findings in daylight photodynamic therapy for skin field cancerization: A randomized controlled four-arm study on physical methods-assisted delivery of methyl aminolevulinate.
Bento Camila de Oliveira, Pantaleão Luciana, de Souza Mariana Boechat et al. · Photodiagnosis Photodyn Ther · 2021
PMID: 34133958RCT
Hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion and methyl aminolevulinate in photodynamic therapy of non-aggressive basal cell carcinomas: A non-sponsored, randomized, prospective and double-blinded trial.
Salmivuori M, Grönroos M, Tani T et al. · J Eur Acad Dermatol Venereol · 2020
PMID: 32196772RCT
Methylene blue vs methyl aminolevulinate photodynamic therapy in the treatment of mild-to-moderate toenail onychomycosis: Short- and medium-term effects.
Alberdi Enrique, Gómez Clara · Dermatol Ther · 2020
PMID: 32890444RCT
Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra-individual study.
Assikar S, Labrunie A, Kerob D et al. · J Eur Acad Dermatol Venereol · 2020
PMID: 31955461RCT
Single versus two-treatment schedule of methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face and scalp: An intra-patient randomized trial.
Gutiérrez García-Rodrigo Carlota, Pellegrini Cristina, Piccioni Antonella et al. · Photodiagnosis Photodyn Ther · 2019
PMID: 31141730RCT
Protoporphyrin IX formation after application of methyl aminolevulinate on the face and scalp with and without prior curettage.
Heerfordt Ida M, Bieliauskiene Giedre, Wulf Hans Christian · Photodiagnosis Photodyn Ther · 2018
PMID: 29601904RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Methyl aminolevulinate (substance)
SNOMED CT
409397005
UMLS CUI
C1134467
RxNorm CUI
337068

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
40
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.